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Experimental Assessment of Effects of Antiproliferative Drugs Used in 
Drug-Eluting Stents on Endothelial Cells
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Abstract
Background: Late and very late stent thrombosis after drug-eluting stent implantation is a 
major concern. The present study evaluated difference in the effects of sirolimus, paclitaxel 
and zotarolimus on endothelial cells.
Methods: Mouse endothelial cells were seeded in a 6-well plate. Cells were cultured with an 
antiproliferative drug at the expected concentrations for each well for 24 hours before making 
3 scratch lines with a pipette tip. After a 4.5 hour incubation period, 3 reference scratch lines, 
vertically across the original scratch lines, were made in the same way. The experiment was 
repeated at least 6 times (6 plates). Measurements were performed at 9 crossings of each well. 
Wound healing ratio was calculated as 1 - (distance of the first scratch/distance of the second 
scratch). % cell migration was calculated as (wound healing ratio at an expected drug 
concentration/wound healing ratio with no drug) × 100. Average % cell migration at 54 
crossings of 6 plates was calculated.
Results: Paclitaxel inhibited cell migration in a concentration-dependent manner. On the other 
hand, concentration-dependent inhibition was not observed for sirolimus or zotarolimus.
Sirolimus showed a stronger inhibitory effect on migration of endothelial cells compared to 
zotarolimus.
Conclusions: The difference in the effect of antiproliferative drugs of drug-eluting stents on
endothelial cells may be associated with relatively faster re-endothelialization of 
zotarolimus-eluting stent compared to the 1st generation DES.
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1. Introduction
Drug-eluting stent (DES) has dramatically reduced in-stent restenosis. However, late 
and very late stent thrombosis after DES implantation has emerged as a major concern. The 
antiproliferative drugs used in DES not only inhibit intimal hyperplasia but also delay 
re-endothelialization. Recent trials have shown a lower stent thrombosis rate of the 2nd
generation DES compared to the 1st generation DES [1]. Thus the effect of the 
antiproliferative drugs of the 1st and 2nd generation DES on re-endothelialization may be 
different. The present experimental study evaluated difference in the effect of the 
antiproliferative drugs of the 1st and 2nd generation DES on endothelial cells.
2. Methods
2.1. Chemicals
Chemicals were purchased from the following commercial sources: paclitaxel (Wako 
Chemicals, Japan), zotarolimus (Toronto Research Chemicals, Canada), and rapamycin 
(Sigma, USA). Ethanol was used as solvent for paclitaxel and rapamycin, and DMSO for 
zotarolimus.
2.2. Cell culture
Mouse ?????????????????????????????????????????????????????????????????????????
BRC through the National Bio-Resource Project of the MEXT, Japan. Cells were cultured at 
37 °C in a 5% CO2, humidified atmosphere. Cells were grown in Dulbecco’s Modified 
Eagle’s Medium (High glucose, Sigma, USA) with 10% fetal bovine serum (HyClone, USA), 
100 units/ml penicillin, and 100 μg/ml streptomycin from Nacalai Tesque (Kyoto, Japan).
2.3. Scratch assay
We assessed the effects of antiproliferative drugs of DES on cultured endothelial 
cells by scratch wound assay. Cells were seeded at the density of 0.7-1.5?105 cells/well in a 
6-well plate. Following the pre-culture period for 24 hour (Figure 1), the volume of culture 
medium in each well was adjusted to 2 ml to start the incubation of cells with a drug at the 
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expected concentrations for each well in the plate. The drug concentrations were selected 
according to those in previous studies [2,3]. Cells were cultured for another 24 hours before 
making 3 scratch lines with a pipette tip (200-μl size), and the closure of the scratch lines was 
measured after a 4.5-hour incubation period. Three reference scratch lines, vertically across 
the original scratch lines, were made in the same way just before fixing cells with 4% 
paraformaldehyde for 10 min at room temperature prior to take images under the microscope 
at 40× magnification (Figure 2) [4]. The images acquired for each sample were analyzed 
quantitatively by using ImageJ 1.48v (NIH, USA). The experiment was repeated at least 6 
times (6 plates).
Cell migration was evaluated by comparing the images between the solvent-treated 
control cells and the drug-treated cells. For each image, measurements were performed at 9 
crossings of each well (Figure 1). The distances of the first scratch and the second scratch 
were measured at 6 points (Figure 2). The mean distances of the first scratch and the second 
scratch were calculated. Wound healing ratio was calculated as 1 - (mean distance of the first 
scratch/mean distance of the second scratch). % cell migration was calculated as (wound 
healing ratio at an expected drug concentration/wound healing ratio with no drug) × 100.
Average % cell migration at 54 crossings of 6 plates was calculated.
2.4. Statistical analysis
Statistical analysis was performed with SAS9.4 (SAS Institute Inc. Cary, NC, USA). 
Values are shown as mean ± SD. Continuous variables were compared using Student’s t test 
or one-way analysis of variance. Statistical significance was defined as p <0.05
3. Results
Paclitaxel inhibited cell migration in a concentration-dependent manner (Figure 3).
On the other hand, concentration-dependent inhibition was not observed for sirolimus or
zotarolimus. Pharmacokinetics of sirolimus-eluting stent and zotarolimus-eluting stent were 
reported [5,6]. However, there is little information about pharmacokinetics of 
paclitaxel-eluting stent. Thus we compared the effect of sirolimus and zotarolimus at the 
4 
 
concentrations that were closest but higher than the maximum concentration after sirolimus-
(0.86 ? 0.21 ng/ml) and zotarolimus-eluting stent implantation (1.80 ? 0.53 ng/ml) [6].
Sirolimus showed a stronger inhibitory effect on migration of endothelial cells compared to 
zotarolimus (Figure 4), although concentration of zotarolimus compared to that after stent 
implantation was much higher than that of sirolimus.
4. Discussion
The present study evaluated effects of antiproliferative drugs of the 1st and 2nd
generation DES on endothelial cells. Inhibition of endothelial cell migration with paclitaxel 
was concentration-dependent. The concentration-dependent inhibition was not observed for 
sirolimus or zotarolimus. Sirolimus inhibited cell migration more than zotarolimus.
The reported incidence of late and very late stent thrombosis after the 1st generation 
DES implantation ranged between 0.2% and 0.7% [7-12]. A cohort study reported that 
definite stent thrombosis continued to occur at the constant rate of 0.6% per year from 30 
days to 3 years after the 1st generation DES implantation [11]. Stent thrombosis often results 
in myocardial infarction or death. Iakovou et al.[12] reported a case fatality rate of stent 
thrombosis at 45%. Recent studies have shown that stent thrombosis is less frequent after 
implantation of the 2nd generation DES compared to the 1st generation DES [13]. It may be 
owing to better stent material, implantation techniques, and antiplatelet therapy. A human 
autopsy study has shown greater strut coverage with less inflammation and fibrin deposition 
after implantation of the 2nd generation DES compared to the 1st generation DES [14].
DES usually consists of 3 components: (1) metallic stent, (2) drug as an 
antiproliferative agent to inhibit neointimal formation, and (3) polymer as a drug-carrier 
vehicle. The cause of stent thrombosis is multifactorial. Patient-related, lesion-related, and 
procedure-related factors may be intertwined. A study demonstrated less thrombogenicity of 
stent with thinner struts [15]. It has been shown that hypersensitivity reaction to the polymer 
of the 1st generation stents is associated with late and very late stent thrombosis [16]. However, 
delayed re-endothelialization due to the antiproliferative drugs of DES may be mainly 
associated with late and very late stent thrombosis [17].
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Paclitaxel inhibits endothelial cell migration and intimal hyperplasia by stabilizing 
microtubules [18,19]. Cytostatic effect of low-dose paclitaxel on human endothelial cells has 
been demonstrated [20]. Because paclitaxel is an anticancer agent, therapeutic window may be 
narrow, which may be associated with delay in re-endothelialization in a 
concentration-dependent manner [21]. Sirolimus [22,23] and zotarolimus [24]
inhibit the mammalian target of rapamycin pathway, which results in the antimigration and 
antiproliferative effect. A previous study evaluated the effects of antiproliferative drugs of 
DES on endothelial progenitor cells [25]. Sirolimus or paclitaxel inhibited endothelial 
progenitor cells migration to a significantly greater degree than zotarolimus. Delayed 
re-endothelialization of DES is a mechanism of late and very late stent thrombosis. Stronger 
inhibitory effect of antiproliferative drugs on migration of endothelial cells may be associated 
with delayed re-endothelialization of DES. Cell migration studies may be useful to find a 
better antiproliferative drug in case a new DES is developed.
5. Limitations
The present study used mouse vascular endothelial cells and compared the effect of 
drugs on cell migration at each concentration based on known pharmacokinetics. The effects 
of antiproliferative drugs might be different between mouse and human endothelial 
cells. Steinfeld et al.[26] used endothelial cell isolated from human coronary arteries and 
reported paclitaxel inhibited cell migration compared with zotarolimus at 1 ??. The study 
compared the effect of drugs on same concentration. However, the effect of actual 
concentrations of each antiproliferative drug at the vascular endothelium adjacent to DES is 
unknown. In addition, endothelialization can be affected by endothelial progenitor cells and 
other kinds of cells. Therefore, further analysis based on more information of 
pharmacokinetics of antiproliferative drugs and using those cells may be needed to assess 
speed of endothelialization more precisely.
6. Conclusions
Inhibition of endothelial cell migration with paclitaxel is concentration-dependent. 
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On the other hand, it is concentration-independent for zotarolimus or sirolimus. Zotarolimus 
has less inhibitory effect compared to sirolimus. It may be associated with relatively faster 
re-endothelialization of zotarolimus-eluting stent compared to the 1st generation DES.
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Figure legends
Fig. 1 Experimental flow chart.
Fig. 2 Measurements of cell migration. The distances of the first scratch line (W1-6) and 
the second scratch line (H1-6) are measured at 6 points. The mean distances of the first 
scratch and the second scratch are calculated. Wound healing ratio was calculated as 1 - (mean 
distance of the first scratch/mean distance of the second scratch).
Fig. 3 The effect of antiproliferative drugs on endothelial cell migration. Paclitaxel inhibits 
cell migration in a concentration-dependent manner. On the other hand, 
concentration-dependent inhibition is not observed for sirolimus or zotarolimus.
Fig. 4 The effect of sirolimus and zotarolimus on endothelial cell migration at the each 
concentration based on pharmacokinetics after stent implantation. Sirolimus shows a stronger 
inhibitory effect on migration of endothelial cells compared to zotarolimus.
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